Prous Institute for Biomedical Research
Overview
Prous Institute for Biomedical Research is a Spanish research and investment firm that partners with and invests in early-stage biomedical projects, including therapeutics, diagnostics, artificial intelligence, and digital health sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Nanobots Therapeutics | Dec 2024 | Seed | Co-investor |
| MedBioinformatics Solutions SL | Feb 2020 | Seed | Co-investor |
| FollowApp Care | Jan 2023 | Seed | Lead |
| Connecta Therapeutics | Sep 2026 | Early Funding | Co-investor |
| D-Sight | Feb 2026 | VC Round | Co-investor |
Key People
David Prous
Co-Founder Executive Director
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Prous Institute for Biomedical Research based?
Prous Institute for Biomedical Research is headquartered in Barcelona, Spain.
When was Prous Institute for Biomedical Research founded?
Prous Institute for Biomedical Research was founded in 2000.
How many portfolio companies does Prous Institute for Biomedical Research have?
Prous Institute for Biomedical Research has 5 portfolio companies in Caplight's dataset.
What are some companies in Prous Institute for Biomedical Research's portfolio?
Portfolio companies visible on Caplight include Nanobots Therapeutics, MedBioinformatics Solutions SL, FollowApp Care, Connecta Therapeutics, D-Sight.
What was Prous Institute for Biomedical Research's most recent investment shown here?
Prous Institute for Biomedical Research's most recent investment in this portfolio sample was in Connecta Therapeutics in 2026.
What sectors does Prous Institute for Biomedical Research focus on?
Prous Institute for Biomedical Research focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software.
What company stages does Prous Institute for Biomedical Research focus on?
Prous Institute for Biomedical Research typically invests at the Early stage.